Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma
Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma
复制标题
DOI：
10.1517/14712598.2015.1029914
复制
发表时间：
2015-06-01
影响因子：
4.6
通讯作者：
Otsuji, Eigo
中科院分区：
文献类型：
--
作者：
Komatsu, Shuhei;Ichikawa, Daisuke;Otsuji, Eigo
背景资料：最近的研究发现，microRNA在血浆/血清中是稳定可检测的，因为它们与特定的蛋白质结合或被包装在分泌囊泡中。方法：我们测试了miR-223作为胰腺癌（PCa）和导管内乳头状粘液性肿瘤（IPMN）的新型血浆生物标志物的候选者。i）miR-223在PCa组织中的表达显著高于正常组织（p = 0.0069）。ii）71名PCa患者的血浆miR-223水平显著高于67名健康志愿者（p < 0.0001）。iii）血浆miR-223水平在术后样品中显著降低（p = 0.0297）。iv）血浆miR-223水平倾向于区分良性IPMN和恶性IPMN之间的恶性潜能（p = 0.0963），以及恶性IPMN和胰腺浸润性导管癌（PIDC）之间的侵袭性的进行性程度（p = 0.0004）。多变量logistic回归分析显示，低水平的血浆miR-223是PIDC的独立风险因素（p = 0.0012，比值比7.90 [95% CI：2.06 - 41.2]）。结论：血浆miR-223可作为PCa筛查、预测IPMN恶性潜能及侵袭性的生物学指标。
Background: Recent studies have identified that microRNAs are stably detectable in plasma/serum because of their binding to specific proteins or being packaged in secretory vesicles.Methods: We tested miR-223 as a candidate of novel plasma biomarker in pancreatic cancer (PCa) and intraductal papillary mucinous neoplasm (IPMN).Results: i) miR-223 expression was significantly higher in PCa tissues (p = 0.0069) than in normal tissues. ii) Plasma miR-223 levels were significantly higher in 71 PCa patients than 67 healthy volunteers (p < 0.0001). iii) Plasma miR-223 levels were significantly reduced in postoperative samples (p = 0.0297). iv) Plasma miR-223 levels tended to discriminate the malignant potential between benign IPMN and malignant IPMN (p = 0.0963), and the progressive extent of invasiveness between malignant IPMN and pancreatic invasive ductal carcinoma (PIDC) (p = 0.0004). Multivariate logistic regression analysis revealed that a low level of plasma miR-223 was an independent risk factor for PIDC (p = 0.0012, odds ratio 7.90 [95% CI: 2.06 - 41.2]). v) There was no significant correlation between plasma miR-223 levels and the number of any blood cell types in the peripheral blood.Conclusion: Plasma miR-223 might be a clinically useful biomarker for screening PCa, and predicting malignant potential of IPMN and the invasiveness of PCa.